chloromethyl hexanoate | 66542-51-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: chloromethyl hexanoate
• 英文别名: chloromethyl (2-ethyl)butyrate
• CAS: 66542-51-6
• 化学式: C₇H₁₃ClO₂
• mdl: MFCD19232012
• 分子量: 164.632
• InChiKey: HNUBMUSOXKDQIN-UHFFFAOYSA-N

物化性质

• 保留指数：
  1051;1069;1072;1084

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  chloromethyl hexanoate 以 乙腈 为溶剂， 反应 25.0h， 生成 1-hexanoyloxymethyl-5-fluorouracil
  参考文献：
  名称：

  1-Alkylcarbonyloxymethyl Prodrugs of 5-Fluorouracil (5-FU): Synthesis, Physicochemical Properties, and Topical Delivery of 5-FU

  摘要：

  1-Alkylcarbonyloxymethyl (1-ACOM) prodrugs of 5-fluorouracil (5-FU) have been synthesized and characterized by their solubilities in isopropyl myristate (SIPM) and pH 4.0 buffer (SH2O), by their partition coefficients between isopropyl myristate (IPM) and pH 4.0 buffer (K) and by their abilities to deliver total 5-FU species into (Cs) and through (Ji) hairless mouse skin from an IPM vehicle. All of the prodrugs were much more lipophilic (SIPM) than 5-FU (> 60 times), and two members of the series (alkyl = C1 and C2, acetyl- and propionyloxymethyl) were also more soluble in water than 5-FU. The two more water-soluble members gave larger Ji values than the other members of the series, with C2 exhibiting the best biphasic solubility and the largest Ji value (16 times that of 5-FU). The ability of the 1-ACOM-5-FU prodrugs to deliver total 5-FU species into skin (Cs) was greater than the delivery of 5-FU by 5-FU, except for the last two members of series (alkyl = C7 and C9, octanoyl- and decanoyl-oxymethyl). However, the ratios of normalized Cs to Ji for the series was less than that exhibited by 5-FU, except for C7 and C9. Also, except for C9, significant amounts of intact prodrug as percentages of total 5-FU species were found in the receptor phases during the course of the diffusion cell experiments, ranging from 55% for C1 to 12% for C7.

  DOI：

  10.1021/js9702574
• 作为产物：
  描述：

  己酰氯 在 聚合甲醛 、 zinc(II) chloride 作用下， 反应 5.0h， 生成 chloromethyl hexanoate
  参考文献：
  名称：

  Prodrugs of NH-acidic compounds

  摘要：

  该发明提供了一种持续释放内酰胺、亚酰胺、酰胺、磺胺、氨基甲酸酯或尿素含有母体药物的方法，通过向患者施用本发明的一种前药化合物的有效量，在患者体内，从前药中释放母体药物是持续释放的。适用于本发明方法的前药化合物是母体药物的不稳定结合物，通过羰基连接的前药基团进行衍生化。本发明的前药化合物可用于治疗任何需要内酰胺、亚酰胺、酰胺、磺胺、氨基甲酸酯或尿素含有母体药物作为治疗的情况。

  公开号：

  US09102618B2

文献信息

• Bioresponsive Deciduous-Charge Amphiphiles for Liposomal Delivery of DNA and siRNA
  作者：Philippe Pierrat、Dimitri Kereselidze、Patrick Wehrung、Guy Zuber、Françoise Pons、Luc Lebeau

  DOI：10.1007/s11095-013-0976-9

  日期：2013.5

  Biolabile cationic lipids were developed for efficient intracellular delivery of DNA and siRNA. The compounds have been designed starting from the membrane lipid DOPC in a way they may loose their cationic charge when exposed to an acidic and/or enzymatic stimulus, such as those met during the journey of a lipoplex in biological media. They demonstrated remarkable efficiency to deliver DNA in various cell lines (BHK-21, Calu-3, NCI-H292, and A549), with no significant cytotoxicity. Furthermore, two of the compounds (carbonate-based DOPC derivatives) revealed able to deliver small interfering RNA in U87Luc and A549Luc cancer cells and to mediate a selective 70–80% knockdown of the stably transfected luciferase gene. The results show that the described bioresponsive cationic lipids have high DNA and siARN delivery activity which is encouraging in view of delivering a therapeutic nucleic acid to pulmonary tissues in vivo.

  生物可降解阳离子脂质是为高效递送DNA和siRNA到细胞内而开发的。这些化合物的设计起点是膜脂DOPC，设计思路是使其在遭受酸性或酶促刺激时，如lipoplex在生物介质中行进过程中遇到的那些刺激，可能失去其阳离子电荷。它们在多种细胞系（BHK-21、Calu-3、NCI-H292和A549）中显示出卓越的DNA递送效率，同时没有显著的细胞毒性。此外，其中两种化合物（碳酸酯基DOPC衍生物）能够将小干扰RNA递送至U87Luc和A549Luc癌细胞，并能介导稳定转染的荧光素酶基因有选择性地70-80%的knockdown效果。结果表明，所述的生物响应性阳离子脂质具有高度的DNA和siRNA递送活性，这对于在体内向肺部组织递送治疗性核酸来说是一个令人鼓舞的发现。
• [EN] PHOSPHOLIPID-DETERGENT CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS DE PHOSPHOLIPIDE-DÉTERGENT ET LEURS UTILISATIONS
  申请人：UNIV STRASBOURG

  公开号：WO2013014073A1

  公开（公告）日：2013-01-31

  The invention relates to novel compounds, in particular novel O-substituted phospholipids that are useful for the in vitro and in vivo delivery of drugs as well as nucleic acids into cells. The invention also relates to pharmaceutical compositions and supramolecular complexes comprising said compounds and the use of these compounds in therapeutic treatment, in particular in gene therapy.

  这项发明涉及新型化合物，特别是新型O-取代磷脂类化合物，可用于体外和体内将药物以及核酸输送到细胞内。该发明还涉及包括所述化合物的药物组合物和超分子复合物，以及这些化合物在治疗治疗中的使用，特别是在基因治疗中。
• Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy
  作者：Boris Gaillard、Cendrine Seguin、Jean‐Serge Remy、Françoise Pons、Luc Lebeau

  DOI：10.1002/chem.201903976

  日期：2019.12.5

  Sixteen cationic prodrugs of the antitumor alkylphospholipid (APL) erufosine were rationally synthesized to provide original gene delivery reagents with improved cytotoxicity profile. The DNA complexation properties of these cationic lipids were determined and associated transfection rates were measured. Furthermore, the self-assembly properties of the pro-erufosine compounds were investigated and

  合理地合成了十六种抗肿瘤烷基磷脂（APL）肌苷的阳离子前药，以提供具有改善的细胞毒性特征的原始基因递送试剂。确定了这些阳离子脂质的DNA络合特性，并测量了相关的转染率。此外，研究了芥子油苷化合物的自组装性能，并确定了其临界聚集浓度。在模拟细胞外环境和晚期内体环境的pH条件下，测量了它们的水解稳定性。研究了这些化合物的溶血活性和细胞毒性。在各种细胞系中获得的结果表明，芥子碱的前药显示出与母体抗肿瘤药相似的抗肿瘤活性，但与溶血毒性无关，这是APL的剂量限制性副作用，是其在APL中使用的主要障碍抗癌治疗方案。此外，通过使用由芥酸前药和编码促凋亡蛋白（TRAIL）的质粒DNA制备的脂质复合物，提供了对肿瘤细胞的选择性细胞毒性而非肿瘤细胞具有抗性的证据。这项研究表明，包括良好耐受的芥酸阳离子前药和癌症基因治疗的组合方法在肿瘤治疗中具有重大前景。此外，通过使用由芥酸前药和编码促凋亡蛋白（TRAIL）的
• [EN] SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS<br/>[FR] RÉACTIFS DE MÉTHYLFORMYLE SUBSTITUÉ ET PROCÉDÉ D'UTILISATION DE CEUX-CI POUR MODIFIER DES PROPRIÉTÉS PHYSICOCHIMIQUES ET/OU PHARMACOCINÉTIQUES DE COMPOSÉS
  申请人：SPHAERA PHARMA PRIVATE LTD

  公开号：WO2012137225A1

  公开（公告）日：2012-10-11

  The present invention relates to the synthesis and application of novel chiral/ achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.

  本发明涉及合成和应用新型手性/非手性取代甲基甲酰试剂，用于修改药物和/或生物活性物质，以改变未经修改的原始试剂产生的化合物的物理化学、生物学和/或药代动力学性质。
• [EN] PRODRUGS OF CGRP ANTAGONISTS<br/>[FR] PROMÉDICAMENTS D'ANTAGONISTES DU CGRP
  申请人：BIOHAVEN PHARM HOLDING CO LTD

  公开号：WO2020077038A1

  公开（公告）日：2020-04-16

  Disclosed are prodrugs of CGRP antagonists, methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof the prodrugs, pharmaceutical compositions comprising prodrugs and kits including the pharmaceutical compositions and instructions for use.

  披露了CGRP拮抗剂的前药，治疗CGRP相关疾病的方法，例如偏头痛，通过向需要的患者给予前药，包含前药的药物组合物以及包括药物组合物和使用说明的工具包。

表征谱图